Âé¶¹´«Ã½

    Advertisement
    Yahoo! UK & Ireland07:13
    The Motley Fool (Australia)01:53
    Yahoo! US20:33
    Benzinga10:22
    Nasdaq12:14
    MorningStar.com14:00
    Yahoo! UK & Ireland11:58
    In the last 4 hours
    Business Wire (Press Release)16:04
    In the last 6 hours
    JD Supra13:37
    The Motley Fool13:13
    Bloomberg Law13:07
    Business Wire (Press Release)13:01
    In the last 8 hours
    Business Wire (Press Release)11:29
    Earlier today
    Yahoo! UK & Ireland08:31
    Proactive Investors (US)08:24
    Pharmaceutical Technology07:37
    EasternEye06:20
    Seeking Alpha06:05
    Yahoo! US05:44
    Yahoo! UK & Ireland04:57
    Business Plus Online03:08
    The Motley Fool (Australia)01:53
    Yesterday
    The Economic Times22:14 29-Jul-25
    The Motley Fool20:56 29-Jul-25
    Yahoo! US20:33 29-Jul-25
    ShareCafe20:06 29-Jul-25
    Business Recorder, Pakistan18:27 29-Jul-25
    This is Money17:42 29-Jul-25
    Boston Globe16:34 29-Jul-25
    Kiplinger.com16:17 29-Jul-25
    Yahoo! UK & Ireland16:03 29-Jul-25
    Yahoo! US15:58 29-Jul-25
    NPR15:49 29-Jul-25
    MorningStar.com14:00 29-Jul-25
    Mint13:44 29-Jul-25
    Benzinga13:35 29-Jul-25
    CBS News13:26 29-Jul-25
    The State, South Carolina13:22 29-Jul-25
    Yahoo! UK & Ireland13:19 29-Jul-25
    The Independent12:45 29-Jul-25
    Bloomberg Law12:31 29-Jul-25
    BioPharma Dive12:20 29-Jul-25
    London South East12:19 29-Jul-25
    Yahoo! UK & Ireland12:18 29-Jul-25
    Nasdaq12:14 29-Jul-25
    Zacks12:02 29-Jul-25
    Yahoo! UK & Ireland11:58 29-Jul-25
    Yahoo! US11:53 29-Jul-25
    24/7 Wall St.11:32 29-Jul-25
    The Irish Independent11:17 29-Jul-25
    Forbes11:13 29-Jul-25
    Financial Mail11:01 29-Jul-25
    BBC10:43 29-Jul-25
    Evening Standard10:40 29-Jul-25
    euronews10:30 29-Jul-25
    FiercePharma10:27 29-Jul-25
    Yahoo! UK & Ireland10:26 29-Jul-25
    Quartz10:22 29-Jul-25
    Yahoo! US10:22 29-Jul-25
    Benzinga10:22 29-Jul-25
    Investing.com UK09:53 29-Jul-25
    Mint09:51 29-Jul-25
    The Economic Times09:49 29-Jul-25
    Fortune09:49 29-Jul-25
    EurActiv.com09:44 29-Jul-25
    Wall Street Pit09:43 29-Jul-25
    UPI09:41 29-Jul-25
    Yahoo! US09:41 29-Jul-25
    STAT09:36 29-Jul-25
    Finance in Bold09:33 29-Jul-25
    Invezz09:13 29-Jul-25
    RTE09:11 29-Jul-25
    France 2409:11 29-Jul-25
    Yahoo! US09:10 29-Jul-25
    IG09:07 29-Jul-25
    Labiotech09:07 29-Jul-25
    Barchart09:07 29-Jul-25
    pharmaphorum09:06 29-Jul-25
    Yahoo! US09:00 29-Jul-25
    Daily Sabah08:52 29-Jul-25
    Yahoo! US08:40 29-Jul-25
    Benzinga08:40 29-Jul-25
    ShareCast08:36 29-Jul-25
    STAT08:35 29-Jul-25
    Novo Nordisk07:54 29-Jul-25
    Yahoo! UK & Ireland07:54 29-Jul-25
    Novo Nordisk07:13 29-Jul-25
    Yahoo! UK & Ireland07:13 29-Jul-25
    In the last 7 days
    The Economic Times15:53 28-Jul-25
    Fox News15:19 28-Jul-25
    Law36013:59 28-Jul-25
    Mint12:09 28-Jul-25
    Yahoo! US06:10 28-Jul-25
    The Economic Times03:55 28-Jul-25
    The Motley Fool11:59 27-Jul-25
    TipRanks18:04 26-Jul-25
    Benzinga12:07 25-Jul-25
    Zacks10:18 25-Jul-25
    Novo Nordisk06:57 25-Jul-25
    Law36017:30 24-Jul-25
    Novo Nordisk17:03 24-Jul-25
    Novo Nordisk17:03 24-Jul-25
    JD Supra12:34 24-Jul-25
    The Hindu Business Line11:33 24-Jul-25
    Zacks10:51 24-Jul-25
    24/7 Wall St.10:33 24-Jul-25
    Pharmaceutical Technology07:14 24-Jul-25
    Law36018:40 23-Jul-25
    Genetic Engineering and Biotechnology News16:58 23-Jul-25
    Benzinga16:28 23-Jul-25
    The Economic Times15:29 23-Jul-25
    Bloomberg Law11:51 23-Jul-25
    Bloomberg Law11:41 23-Jul-25
    Bloomberg Law11:31 23-Jul-25
    Zacks10:55 23-Jul-25
    Zacks10:45 23-Jul-25
    DatacenterDynamics10:45 23-Jul-25
    European Pharmaceutical Manufacturer10:32 23-Jul-25
    The Economic Times10:24 23-Jul-25
    Seeking Alpha01:31 23-Jul-25
    In the last month
    Evertiq09:05 22-Jul-25
    Drug & Device Law05:43 22-Jul-25
    view more headlines
    30 Jul 16:04

    About our Novo Nordisk news

    Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

    Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

    Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

    In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

    Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

    As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our Âé¶¹´«Ã½ feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.